Norges Bank Sana Biotechnology, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.23 - $10.44 $1.31 Million - $2.61 Million	249,621 New	249,621 $1.36 Million
Q4 2023 Feb 09, 2024	BUY	$2.8 - $4.55 $698,938 - $1.14 Million	249,621 New	249,621 $1.02 Million
Q3 2023 Nov 13, 2024	BUY	$3.77 - $6.23 $941,071 - $1.56 Million	249,621 New	249,621 $966,000
Q3 2023 Nov 13, 2023	SELL	$3.77 - $6.23 $941,071 - $1.56 Million	-249,621 Closed	0 $0
Q2 2023 Aug 14, 2023	SELL	$3.22 - $7.53 $803,779 - $1.88 Million	-249,621 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$3.11 - $4.92 $776,321 - $1.23 Million	249,621 New	249,621 $816,000
Q4 2022 Feb 14, 2023	BUY	$3.19 - $6.46 $796,290 - $1.61 Million	249,621 New	249,621 $986,000
Q3 2022 Nov 13, 2023	BUY	$5.58 - $9.04 $1.39 Million - $2.26 Million	249,621 New	249,621 $1.5 Million
Q2 2022 Aug 14, 2023	BUY	$4.12 - $9.35 $1.03 Million - $2.33 Million	249,621 New	249,621 $1.61 Million
Q1 2022 May 12, 2023	SELL	$5.24 - $15.58 $1.16 Million - $3.44 Million	-220,751 Reduced 88.43%	28,870 $238,000
Q1 2022 May 09, 2022	SELL	$5.24 - $15.58 $151,278 - $449,794	-28,870 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$15.18 - $23.15 $438,246 - $668,340	28,870 New	28,870 $447,000

174

121M

1.87M

1.48M

Ticker SANA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 190,232,000
Market Cap $314M
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.